EFFECTS OF BUCILLAMINE, A NEW ANTIRHEUMATIC DRUG, ON THE EXPERIMENTAL AUTOIMMUNE UVEITIS IN RATS

被引:4
作者
SAWA, K
MOCHIZUKI, M
机构
[1] Department of Ophthalmology, Kurume University School of Medicine, Kurume, 830
关键词
BUCILLAMINE; CYCLOSPORINE A; ANTIRHEUMATIC DRUG; IMMUNOMODULATOR; EXPERIMENTAL AUTOIMMUNE UVEITIS; S-ANTIGEN; COMBINATION THERAPY; RATS;
D O I
10.1006/exer.1994.1036
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
The in vitro and in vivo effects of a new immunomodulating agent, bucillamine, on experimental autoimmune uveitis (EAU) was studied in the rat. The capacity of S-antigen-sensitized lymphocytes to proliferate in response to the antigen or to produce antigen-specific antibodies was significantly suppressed by bucillamine in culture in a dose-dependent manner. The inhibitory effect of bucillamine was significantly enhanced by adding cyclosporin A (CYA) in the culture. The in vivo effects of bucillamine alone or in combination with CYA were further examined in Lewis rats immunized with S-antigen. All untreated rats developed severe EAU 17 days after S-antigen immunization, while rats treated with either bucillamine (200 mg kg-1 day-1) or CYA (2 mg kg-1 day-1) demonstrated milder symptoms of EAU. A combination therapy with bucillamine (20 or 200 mg kg-1 day-1) and CYA (2 mg kg-1 day-1) exhibited much more significant suppression of EAU induction. Although the in vivo treatment with bucillamine or CYA had no effects on the T-cell populations of spleen cells, the combination therapy significantly decreased the CD4+ T-cell population. As for the immune responses to S-antigen in drug-treated rats, bucillamine suppressed the lymphocyte proliferation to S-antigen, which was further suppressed by combination therapy with CYA. The serum antibody levels specific to S-antigen were not affected by tested dose of bucillamine. © 1994 Academic Press. All rights reserved.
引用
收藏
页码:431 / 438
页数:8
相关论文
共 24 条
  • [1] ABE C, 1985, INT J IMMUNOTHER, V1, P7
  • [2] A SIMPLE AND RAPID METHOD FOR ISOLATION OF RETINAL S ANTIGEN
    DOREY, C
    COZETTE, J
    FAURE, JP
    [J]. OPHTHALMIC RESEARCH, 1982, 14 (04) : 249 - 255
  • [3] Faure J P, 1980, Curr Top Eye Res, V2, P215
  • [4] PHARMACOLOGICAL STUDIES OF NEW SULFHYDRYL COMPOUNDS 2-MERCAPTO-2-METHYLPRO-PANOYL-L-CYSTEINE(SA96) .1. EVALUATION OF ANTI-RHEUMATIC ACTION
    FUJIMURA, H
    HIRAMATSU, Y
    TAMURA, Y
    YANAGIHARA, M
    KODA, A
    NAGAI, H
    UDA, K
    ISO, T
    YAMAUCHI, H
    [J]. FOLIA PHARMACOLOGICA JAPONICA, 1980, 76 (02) : 117 - 129
  • [5] CYCLOSPORINE-INDUCED SPECIFIC UNRESPONSIVENESS TO RETINAL SOLUBLE-ANTIGEN IN EXPERIMENTAL AUTOIMMUNE UVEORETINITIS
    FUJINO, Y
    OKUMURA, A
    NUSSENBLATT, RB
    GERY, I
    MOCHIZUKI, M
    [J]. CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1988, 46 (02): : 234 - 248
  • [6] GERY I, 1986, INVEST OPHTH VIS SCI, V27, P1296
  • [7] DECREASE IN DISEASE-ACTIVITY AND CONCOMITANT INCREASE IN THE PERCENTAGE OF PERIPHERAL-BLOOD SUPPRESSOR T-CELLS IN RHEUMATOID-ARTHRITIS BY A NEWLY SYNTHESIZED SLOW-ACTING ANTI-RHEUMATIC DRUG (BUCILLAMINE)
    GOTO, M
    SASANO, M
    NISHIOKA, K
    [J]. INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1989, 11 (04): : 327 - 331
  • [8] STIMULATION OF INTERLEUKIN-1-ALPHA AND INTERLEUKIN-1-BETA RELEASE FROM HUMAN-MONOCYTES BY CYANOGEN-BROMIDE PEPTIDES OF TYPE-II COLLAGEN
    GOTO, M
    YOSHINOYA, S
    MIYAMOTO, T
    SASANO, M
    OKAMOTO, M
    NISHIOKA, K
    TERATO, K
    NAGAI, Y
    [J]. ARTHRITIS AND RHEUMATISM, 1988, 31 (12): : 1508 - 1514
  • [9] ISO T, 1985, INT J IMMUNOTHER, V1, P93
  • [10] KASHIWAZAKI S, 1987, INT J IMMUNOTHER, V3, P1